Please use this identifier to cite or link to this item:
|Title:||Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer|
|Source:||Tan, E.-H., Goss, G.D., Salgia, R., Besse, B., Gandara, D.R., Hanna, N.H., Yang, J.C.-H., Thertulien, R., Wertheim, M., Mazieres, J., Hensing, T., Lee, C., Gupta, N., Pradhan, R., Qian, J., Qin, Q., Scappaticci, F.A., Ricker, J.L., Carlson, D.M., Soo, R.A. (2011-08). Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 6 (8) : 1418-1425. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e318220c93e|
|Abstract:||This study assessed activity and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, in patients with locally advanced or metastatic non-small cell lung cancer. Methods: In this open-label trial (NCT00517790), patients who received one to two prior lines of systemic therapy were randomized to oral linifanib 0.10 mg/kg (low dose) or 0.25 mg/kg (high dose) once daily. Tumor responses were assessed by independent central imaging review every 8 weeks. The primary end point was progression-free rate at 16 weeks. Secondary end points included objective response rate, time to progression, progression-free survival, and overall survival. Safety was also assessed. Results: Between August 2007 and October 2008, 139 patients were enrolled; 60% had two or more prior regimens, and 88% had nonsquamous cell carcinoma. The objective response rate (low dose and high dose) was 5.0% (3.1 and 6.8%), progression-free rate at 16 weeks was 33.1% (32.3 and 33.8%), median time to progression was 3.6 months (3.6 and 3.7 months), median progression-free survival was 3.6 months (3.5 and 3.6 months), and median overall survival was 9.0 months (10.0 and 8.3 months). The most common linifanib-related adverse events were fatigue (42%), decreased appetite (38%), hypertension (37%), diarrhea (32%), nausea (27%), palmar-plantar erythrodysesthesia (24%), and proteinuria (22%). These events were more common in the high-dose group. The most common linifanib-related grade 3 or 4 adverse event was hypertension (14%). Conclusions: Linifanib is active in advanced non-small cell lung cancer as second- or third-line therapy. Increased adverse event rates were observed at the high dose of linifanib. Copyright © 2011 by the International Association for the Study of Lung Cancer.|
|Source Title:||Journal of Thoracic Oncology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 7, 2018
WEB OF SCIENCETM
checked on Feb 5, 2018
checked on Mar 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.